Clinical Trial Update: Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating pacritinib in combination with a BTK inhibitor for relapsed or refractory mantle cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• BTK inhibitor
• Pacritinib (pacritinib)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | Phase 1 | Status: RECRUITING